Shorter remission telomere length predicts delayed neutrophil recovery after acute myeloid Leukemia therapy: A report from the children's oncology group

Journal of Clinical Oncology

Volumn 34, Issue 31, 2016, Pages 3766-3772

  Gerbing, Robert B ^a   Alonzo, Todd A ^a,b   Sung, Lillian ^c   Gamis, Alan S ^d   Meshinchi, Soheil ^e   Plon, Sharon E ^f   Bertuch, Alison A ^f   Gramatges, Maria M ^f  

^a Children's Oncology Group   (Liberia)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c HOSPITAL FOR SICK CHILDREN   (Canada)

^d CHILDREN S MERCY HOSPITAL   (United States)

^e UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^f BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD135 ANTIGEN; GEMTUZUMAB OZOGAMICIN; TELOMERASE REVERSE TRANSCRIPTASE; ANTINEOPLASTIC AGENT;

ADOLESCENT; ARTICLE; BONE MARROW BIOPSY; CANCER CHEMOTHERAPY; CHILD; CHILDHOOD LEUKEMIA; COHORT ANALYSIS; DE NOVO ACUTE MYELOID LEUKEMIA; DISEASE DURATION; FEMALE; GENE FREQUENCY; GERMLINE MUTATION; HUMAN; INDUCTION CHEMOTHERAPY; LEUKEMIA REMISSION; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; NEUTROPHIL; NEUTROPHIL COUNT; POLYMERASE CHAIN REACTION; PRESCHOOL CHILD; PRIORITY JOURNAL; QUANTITATIVE ASSAY; TELOMERE HOMEOSTASIS; TELOMERE LENGTH; ACUTE DISEASE; DRUG EFFECTS; GENETICS; INFANT; KAPLAN MEIER METHOD; METABOLISM; MYELOID LEUKEMIA; OUTCOME ASSESSMENT; PATHOLOGY; PROCEDURES; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; REMISSION; STATISTICS AND NUMERICAL DATA; TELOMERE;

ACUTE DISEASE; ADOLESCENT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; FEMALE; HUMANS; INFANT; KAPLAN-MEIER ESTIMATE; LEUKEMIA, MYELOID; MALE; NEUTROPHILS; OUTCOME ASSESSMENT (HEALTH CARE); PROGNOSIS; PROPORTIONAL HAZARDS MODELS; REMISSION INDUCTION; TELOMERE;

EID: 84993929234     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2016.66.9622     Document Type: Article

References (33)

1. Gamis AS, Alonzo TA, Meshinchi S, et al: Gemtuzumab ozogamicin in children and adolescents with de novo acute myeloid leukemia improves event-free survival by reducing relapse risk: Results from the randomized phase III Children's Oncology Group trial AAML0531. J Clin Oncol 32:3021-3032, 2014
2. Lange BJ, Smith FO, Feusner J, et al: Outcomes in CCG-2961, a Children's Oncology Group phase 3 trial for untreated pediatric acute myeloid leukemia: A report from the Children's Oncology Group. Blood 111:1044-1053, 2008
3. Bodey GP, Buckley M, Sathe YS, et al: Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med 64:328-340, 1966
4. Sung L, Lange BJ, Gerbing RB, et al: Micro-biologically documented infections and infection-related mortality in children with acute myeloid leukemia. Blood 110:3532-3539, 2007
5. Iwama H, Ohyashiki K, Ohyashiki JH, et al: Telomeric length and telomerase activity vary with age in peripheral blood cells obtained from normal individuals. Hum Genet 102:397-402, 1998
6. Vaziri H, Dragowska W, Allsopp RC, et al: Evidence for a mitotic clock in human hematopoietic stem cells: Loss of telomeric DNA with age. Proc Natl Acad Sci USA 91:9857-9860, 1994
7. Chiang YJ, Calado RT, Hathcock KS, et al: Telomere length is inherited with resetting of the telomere set-point. Proc Natl Acad Sci USA 107: 10148-10153, 2010
8. Diker-Cohen T, Uziel O, Szyper-Kravitz M, et al: The effect of chemotherapy on telomere dynamics: Clinical results and possible mechanisms. Leuk Lymphoma 54:2023-2029, 2013
9. Lee JJ, Nam CE, Cho SH, et al: Telomere length shortening in non-Hodgkin's lymphoma patients undergoing chemotherapy. Ann Hematol 82: 492-495, 2003
10. Schröder CP, Wisman GB, de Jong S, et al: Telomere length in breast cancer patients before and after chemotherapy with or without stem cell transplantation. Br J Cancer 84:1348-1353, 2001
11. Artandi SE, Attardi LD: Pathways connecting telomeres and p53 in senescence, apoptosis, and cancer. Biochem Biophys Res Commun 331: 881-890, 2005
12. Allsopp RC, Vaziri H, Patterson C, et al: Telomere length predicts replicative capacity of human fibroblasts. Proc Natl Acad Sci USA 89:10114-10118, 1992
13. Wang J, Lu X, Sakk V, et al: Senescence and apoptosis block hematopoietic activation of quiescent hematopoietic stem cells with short telomeres. Blood 124:3237-3240, 2014
14. Balakumaran A, Mishra PJ, Pawelczyk E, et al: Bone marrow skeletal stem/progenitor cell defects in dyskeratosis congenita and telomere biology disorders. Blood 125:793-802, 2015
15. Alter BP, Rosenberg PS, Giri N, et al: Telomere length is associated with disease severity and declines with age in dyskeratosis congenita. Haematologica 97:353-359, 2012
16. Alter BP, Giri N, Savage SA, et al: Cancer in dyskeratosis congenita. Blood 113:6549-6557, 2009
17. Hills M, Lansdorp PM: Short telomeres resulting from heritable mutations in the telomerase reverse transcriptase gene predispose for a variety of malignancies. Ann N Y Acad Sci 1176:178-190, 2009
18. Calado RT, Regal JA, Hills M, et al: Constitutional hypomorphic telomerase mutations in patients with acute myeloid leukemia. Proc Natl Acad Sci USA 106:1187-1192, 2009
19. Aalbers AM, Calado RT, Young NS, et al: Telomere length and telomerase complex mutations in pediatric acute myeloid leukemia. Leukemia 27: 1786-1789, 2013
20. Gramatges MM, Liu Q, Yasui Y, et al: Telomere content and risk of second malignant neoplasm in survivors of childhood cancer: A report from the Childhood Cancer Survivor Study. Clin Cancer Res 20:904-911, 2014
21. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53: 457-481, 1958
22. Cox DR: Regression models and life tables. J R Stat Soc [Ser A] 34:187-220, 1972
23. Sung L, Aplenc R, Alonzo TA, et al: Effectiveness of supportive care measures to reduce infections in pediatric AML: A report from the Children's Oncology Group. Blood 121:3573-3577, 2013
24. Allsopp RC, Cheshier S, Weissman IL: Telomere shortening accompanies increased cell cycle activity during serial transplantation of hematopoietic stem cells. J Exp Med 193:917-924, 2001
25. Widmann T, Kneer H, König J, et al: Sustained telomere erosion due to increased stem cell turnover during triple autologous hematopoietic stem cell transplantation. Exp Hematol 36:104-110, 2008
26. Lobetti-Bodoni C, Ferrero D, Genuardi E, et al: Telomere loss in Philadelphia-negative hematopoiesis after successful treatment of chronic myeloid leukemia: Evidence for premature aging of the myeloid compartment. Mech Ageing Dev 133:479-488, 2012
27. Dietz AC, Orchard PJ, Baker KS, et al: Diseasespecific hematopoietic cell transplantation: Nonmyeloablative conditioning regimen for dyskeratosis congenita. Bone Marrow Transplant 46:98-104, 2011
28. Gluckman E, Devergie A, Schaison G, et al: Bone marrow transplantation in Fanconi anaemia. Br J Haematol 45:557-564, 1980
29. Cronkhite JT, Xing C, Raghu G, et al: Telomere shortening in familial and sporadic pulmonary fibrosis. Am J Respir Crit Care Med 178:729-737, 2008
30. Ballew BJ, Savage SA: Updates on the biology and management of dyskeratosis congenita and related telomere biology disorders. Expert Rev Hematol 6:327-337, 2013
31. Kocak H, Ballew BJ, Bisht K, et al: HoyeraalHreidarsson syndrome caused by a germline mutation in the TEL patch of the telomere protein TPP1. Genes Dev 28:2090-2102, 2014
32. Walter D, Lier A, Geiselhart A, et al: Exit from dormancy provokes DNA-damage-induced attrition in haematopoietic stem cells. Nature 520:549-552, 2015
33. Baerlocher GM, Vulto I, de Jong G, et al: Flow cytometry and FISH to measure the average length of telomeres (flow FISH). Nat Protoc 1:2365-2376, 2006